A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Launched by HOFFMANN-LA ROCHE · May 17, 2007
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients, \>=18 years of age;
- • refractory, relapsing or chronic idiopathic thrombocytopenic purpura;
- • stable therapy during 3 weeks prior to study entry.
- Exclusion Criteria:
- • newly diagnosed ITP (\<6 weeks);
- • prior treatment with MabThera;
- • active bleeding requiring platelet transfusion within 7 days prior to entry into study.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Adelaide, South Australia, Australia
Gosford, New South Wales, Australia
Westmead, New South Wales, Australia
Malvern, Victoria, Australia
Woolloongabba, Queensland, Australia
Frankston, Victoria, Australia
Parkville, Victoria, Australia
Melbourne, Victoria, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Adelaide, South Australia, Australia
Melbourne, Victoria, Australia
Randwick, New South Wales, Australia
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials